Antigen-MHC Nanoparticle Complexes for MS Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for multiple sclerosis (MS) are often poorly tolerated and have significant side effects, with a need for more effective and better-tolerated treatments that can manage the disease effectively without compromising systemic immunity.
Innovation Solution
Administration of antigen-MHC-nanoparticle complexes, specifically designed to expand anti-pathogenic autoreactive T-cells, which are biocompatible and bioabsorbable, to treat or prevent MS by targeting multiple sclerosis-related antigens, thereby reducing disease severity and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MS medications are used, then MS attacks can be eased and disease progression can be slowed, but significant side effects and poor tolerance occur
Solution Approach 1:
The patent uses nanoparticle complexes as intermediary carriers that deliver antigen-MHC complexes to T-cells. These nanoparticles serve as a mediator between the therapeutic agent and the immune system, enabling targeted delivery while minimizing off-target effects and improving tolerance compared to conventional medications.
Solution Approach 2:
The invention applies local quality by targeting specific T-cell populations with antigen-MHC-nanoparticle complexes in a localized manner. The therapy is designed to act specifically on pathogenic T-cells while preserving overall immune function, thereby reducing system-wide side effects while maintaining therapeutic effectiveness in the CNS.
2Reliability
If therapies are developed to expand anti-pathogenic autoreactive T-cells, then MS symptoms can be reduced, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent merges multiple functions into a single nanoparticle complex: the nanoparticle serves as both the delivery vehicle and the presentation platform for antigen-MHC complexes. This consolidation simplifies the treatment protocol by eliminating the need for separate administration of multiple agents, while still achieving the goal of expanding anti-pathogenic T-cells.
3Reliability
If apoptosis-inducing molecules are used for tolerance induction, then antigen-specific tolerance can be achieved, but significant side effects occur
Solution Approach 1:
The patent converts the potentially harmful effect of apoptosis-inducing molecules into a beneficial tolerance induction mechanism. By using nanoparticle-delivered antigen-MHC complexes to activate regulatory T-cells, the therapy achieves antigen-specific tolerance without the severe side effects associated with direct apoptosis induction, effectively turning a harmful mechanism into a beneficial therapeutic approach.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.